Blow to Bioject as Roche and Trimeris drop needle-free Fuzeon project
This article was originally published in Clinica
Executive Summary
Hoffmann-La Roche and Trimeris have withdrawn their FDA submission for the Biojector 2000 formulation of the HIV therapy Fuzeon (enfuvirtide). The product was the result of a long-running collaboration with needle-free drug delivery specialist Bioject Medical Technologies, the Portland, Oregon-based developer of the Biojector 2000 (B2000) device.